Advertisement

The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials

      Abstract

      Objective

      The study objective was to evaluate and update the safety data from randomized controlled trials of tumor necrosis factor inhibitors in patients treated for rheumatoid arthritis.

      Methods

      A systematic literature search was conducted from 1990 to May 2013. All studies included were randomized, double-blind, controlled trials of patients with rheumatoid arthritis that evaluated adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab treatment. The serious adverse events and discontinuation rates were abstracted, and risk estimates were calculated by Peto odds ratios (ORs).

      Results

      Forty-four randomized controlled trials involving 11,700 subjects receiving tumor necrosis factor inhibitors and 5901 subjects receiving placebo or traditional disease-modifying antirheumatic drugs were included. Tumor necrosis factor inhibitor treatment as a group was associated with a higher risk of serious infection (OR, 1.42; 95% confidence interval [CI], 1.13-1.78) and treatment discontinuation due to adverse events (OR, 1.23; 95% CI, 1.06-1.43) compared with placebo and traditional disease-modifying antirheumatic drug treatments. Specifically, patients taking adalimumab, certolizumab pegol, and infliximab had an increased risk of serious infection (OR, 1.69, 1.98, and 1.63, respectively) and showed an increased risk of discontinuation due to adverse events (OR, 1.38, 1.67, and 2.04, respectively). In contrast, patients taking etanercept had a decreased risk of discontinuation due to adverse events (OR, 0.72; 95% CI, 0.55-0.93). Although ORs for malignancy varied across the different tumor necrosis factor inhibitors, none reached statistical significance.

      Conclusions

      These meta-analysis updates of the comparative safety of tumor necrosis factor inhibitors suggest a higher risk of serious infection associated with adalimumab, certolizumab pegol, and infliximab, which seems to contribute to higher rates of discontinuation. In contrast, etanercept use showed a lower rate of discontinuation. These data may help guide clinical comparative decision making in the management of rheumatoid arthritis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Taylor P.C.
        • Feldmann M.
        Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
        Nat Rev Rheumatol. 2009; 5: 578-582
        • Bongartz T.
        • Sutton A.J.
        • Sweeting M.J.
        • Buchan I.
        • Matteson E.L.
        • Montori V.
        Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies.
        JAMA. 2006; 295: 2275
        • Leombruno J.P.
        • Einarson T.R.
        • Keystone E.C.
        The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
        Ann Rheum Dis. 2009; 68: 1136-1145
        • Thompson A.E.
        • Rieder S.W.
        • Pope J.E.
        Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
        Arthritis Rheum. 2011; 63: 1479-1485
        • Singh J.A.
        • Wells G.A.
        • Christensen R.
        • et al.
        Adverse effects of biologics: a network meta-analysis and Cochrane overview.
        Cochrane Database Syst Rev. 2011; : CD008794
        • Aaltonen K.J.
        • Virkki L.M.
        • Malmivaara A.
        • Konttinen Y.T.
        • Nordström D.C.
        • Blom M.
        Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
        PLoS One. 2012; 7: e30275
        • Lopez-Olivo M.A.
        • Tayar J.H.
        • Martinez-Lopez J.A.
        • et al.
        Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.
        JAMA. 2012; 308: 898-908
        • Singh J.A.
        • Christensen R.
        • Wells George A.
        • et al.
        Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
        Cochrane Database Syst Rev. 2009; : CD007848
        • Scott D.
        • Kingsley G.
        Tumor necrosis factor inhibitors for rheumatoid arthritis.
        N Engl J Med. 2006; 355: 704-712
      1. FDA. SIMPONI® (Golimumab) Summary Review. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm152822.pdf. Accessed August 20, 2014.

      2. FDA. CIMZIA® (certolizumab pegol)) Medication Guide. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm088571.pdf. Accessed August 20, 2014.

        • Counsell C.
        Formulating questions and locating primary studies for inclusion in systematic reviews.
        Ann Intern Med. 1997; 127: 380-387
        • Arnett F.
        Revised criteria for the classification of rheumatoid arthritis.
        Bull Rheum Dis. 1989; 38: 1-6
        • Saag K.G.
        • Teng G.G.
        • Patkar N.M.
        • et al.
        American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
        Arthritis Care Res. 2008; 59: 762-784
        • Westhovens R.
        • Yocum D.
        • Han J.
        • et al.
        The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
        Arthritis Rheum. 2006; 54: 1075-1086
        • Klareskog L.
        • van der Heijde D.
        • de Jager J.P.
        • et al.
        Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
        Lancet. 2004; 363: 675-681
      3. National Cancer Institute. Available at: http://www.cancer.gov/dictionary?cdrid=45771. Accessed March 17, 2014.

      4. Higgins J, Green S. Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available at: http://handbook.cochrane.org/. Accessed August 20, 2014.

        • Guyatt G.
        • Oxman A.D.
        • Akl E.A.
        • et al.
        GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables.
        J Clin Epidemiol. 2011; 64: 383-394
        • Balshem H.
        • Helfand M.
        • Schünemann H.J.
        • et al.
        GRADE guidelines: 3. Rating the quality of evidence.
        J Clin Epidemiol. 2011; 64: 401-406
        • Oxman A.D.
        • Group G.W.
        Grading quality of evidence and strength of recommendations.
        BMJ. 2004; 328: 1490-1494
      5. Higgins DJPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Available at: http://tectutorials.com/Resources/AHRQ%20Modules/UoCTrainingMaterials/CochraneHB/booktext.pdf. Accessed August 20, 2014.

        • Laupacis A.
        • Sackett D.L.
        • Roberts R.S.
        An assessment of clinically useful measures of the consequences of treatment.
        N Engl J Med. 1988; 318: 1728
        • Altman D.G.
        Confidence intervals for the number needed to treat.
        BMJ. 1998; 317: 1309
        • Fu R.
        • Gartlehner G.
        • Grant M.
        • et al.
        Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program.
        J Clin Epidemiol. 2011; 64: 1187-1197
        • Rücker G.
        • Schwarzer G.
        • Carpenter J.
        • Olkin I.
        Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta analysis with zero cells.
        Stat Med. 2009; 28: 721-738
      6. Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Version 5.1.0 [updated March 2011]. Available at: http://handbook.cochrane.org/. Accessed August 20, 2014.

        • Higgins J.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557
        • Higgins J.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Wallace B.
        • Schmid C.
        • Lau J.
        • Trikalinos T.
        Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data.
        BMC Med Res Methodol. 2009; 9: 80
        • van de Putte L.B.
        • Rau R.
        • Breedveld F.C.
        • et al.
        Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
        Ann Rheum Dis. 2003; 62: 1168-1177
        • Weinblatt M.E.
        • Keystone E.C.
        • Furst D.E.
        • et al.
        Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
        Arthritis Rheum. 2003; 48: 35-45
        • Keystone E.C.
        • Schiff M.H.
        • Kremer J.M.
        • et al.
        Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
        Arthritis Rheum. 2004; 50: 353-363
        • van de Putte L.B.
        • Atkins C.
        • Malaise M.
        • et al.
        Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
        Ann Rheum Dis. 2004; 63: 508-516
        • Miyasaka N.
        Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study.
        Mod Rheumatol. 2008; 18: 252-262
        • Breedveld F.C.
        • Weisman M.H.
        • Kavanaugh A.F.
        • et al.
        The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
        Arthritis Rheum. 2006; 54: 26-37
        • Kim H.Y.
        • Lee S.K.
        • Song Y.W.
        • et al.
        A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate.
        APLAR J Rheumatol. 2007; : 9-16
        • Bejarano V.
        • Quinn M.
        • Conaghan P.G.
        • et al.
        Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.
        Arthritis Rheum. 2008; 59: 1467-1474
        • Furst D.E.
        • Schiff M.H.
        • Fleischmann R.M.
        • et al.
        Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
        J Rheumatol. 2003; 30: 2563-2571
        • Kavanaugh A.
        • Fleischmann R.M.
        • Emery P.
        • et al.
        Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
        Ann Rheum Dis. 2013; 72: 64-71
        • Detert J.
        • Bastian H.
        • Listing J.
        • et al.
        Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
        Ann Rheum Dis. 2013; 72: 844-850
        • Moreland L.W.
        • Schiff M.H.
        • Baumgartner S.W.
        • et al.
        Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
        Ann Intern Med. 1999; 130: 478-486
        • Bathon J.M.
        • Martin R.W.
        • Fleischmann R.M.
        • et al.
        A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1586-1593
        • Combe B.
        • Codreanu C.
        • Fiocco U.
        • et al.
        Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
        Ann Rheum Dis. 2006; 65: 1357-1362
        • van der Heijde D.
        • Klareskog L.
        • Rodriguez-Valverde V.
        • et al.
        Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
        Arthritis Rheum. 2006; 54: 1063-1074
        • van der Heijde D.
        • Klareskog L.
        • Landewé R.
        • et al.
        Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
        Arthritis Rheum. 2007; : 3928-3939
        • Weisman M.H.
        • Paulus H.E.
        • Burch F.X.
        • et al.
        A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
        Rheumatology (Oxford). 2007; 46: 1122-1125
        • Emery P.
        • Breedveld F.C.
        • Hall S.
        • et al.
        Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
        Lancet. 2008; 372: 375-382
        • Combe B.
        • Codreanu C.
        • Fiocco U.
        • et al.
        Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
        Ann Rheum Dis. 2009; 68: 1146-1152
        • Emery P.
        • Breedveld F.
        • van der Heijde D.
        • et al.
        Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
        Arthritis Rheum. 2010; 62: 674-682
        • Hu D.
        • Bao C.
        • Chen S.
        • et al.
        A comparison study of a recombinant tumor necrosis factor receptor: Fc fusion protein (rhTNFR: Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China.
        Rheum Int. 2009; 29: 297-303
        • Moreland L.W.
        • O'Dell J.R.
        • Paulus H.E.
        • et al.
        A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial.
        Arthritis Rheum. 2012; 64: 2824-2835
        • Maini R.N.
        • Breedveld F.C.
        • Kalden J.R.
        • et al.
        Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
        Arthritis Rheum. 1998; 41: 1552-1563
        • Maini R.N.
        • St Clair E.W.
        • Breedveld F.C.
        • et al.
        Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
        Lancet. 1999; 354: 1932-1939
        • Lipsky P.E.
        • van der Heijde D.M.
        • St Clair E.W.
        • et al.
        Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
        N Engl J Med. 2000; : 1594-1602
        • Maini R.N.
        • Breedveld F.C.
        • Kalden J.R.
        • et al.
        Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
        Arthritis Rheum. 2004; 50: 1051-1065
        • St Clair E.W.
        • van der Heijde D.M.
        • Smolen J.S.
        • et al.
        Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
        Arthritis Rheum. 2004; 50: 3432-3443
        • Zhang F.C.
        • Hou Y.
        • Huang F.
        • et al.
        Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China.
        APLAR J Rheumatol. 2006; : 127-130
        • Schiff M.
        • Keiserman M.
        • Codding C.
        • et al.
        Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
        Ann Rheum Dis. 2008; 67: 1096-1103
        • van Vollenhoven R.F.
        • Ernestam S.
        • Geborek P.
        • et al.
        Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
        Lancet. 2009; 374: 459-466
        • Choy E.
        • McKenna F.
        • Vencovsky J.
        • et al.
        Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
        Rheumatology (Oxford). 2012; 51: 1226-1234
        • Fleischmann R.
        • Vencovsky J.
        • van Vollenhoven R.F.
        • et al.
        Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
        Ann Rheum Dis. 2009; 68: 805-811
        • Keystone E.
        • Heijde D.
        • Mason Jr., D.
        • et al.
        Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
        Arthritis Rheum. 2008; 58: 3319-3329
        • Smolen J.
        • Landewe R.B.
        • Mease P.
        • et al.
        Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
        Ann Rheum Dis. 2009; 68: 797-804
        • Weinblatt M.E.
        • Fleischmann R.
        • Huizinga T.W.
        • et al.
        Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
        Rheumatology (Oxford). 2012; 51: 2204-2214
        • Emery P.
        • Fleischmann R.M.
        • Moreland L.W.
        • et al.
        Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
        Arthritis Rheum. 2009; 60: 2272-2283
        • Kay J.
        • Matteson E.L.
        • Dasgupta B.
        • et al.
        Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
        Arthritis Rheum. 2008; 58: 964-975
        • Keystone E.C.
        • Genovese M.C.
        • Klareskog L.
        • et al.
        Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
        Ann Rheum Dis. 2009; 68: 789-796
        • Kremer J.
        • Ritchlin C.
        • Mendelsohn A.
        • et al.
        Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
        Arthritis Rheum. 2010; 62: 917-928
        • Tanaka Y.
        • Harigai M.
        • Takeuchi T.
        • et al.
        Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.
        Ann Rheum Dis. 2012; 71: 817-824
        • Weinblatt M.E.
        • Bingham C.O.
        • Mendelsohn A.M.
        • et al.
        Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
        Ann Rheum Dis. 2013; 72: 381-389
        • Takeuchi T.
        • Harigai M.
        • Tanaka Y.
        • et al.
        Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.
        Ann Rheum Dis. 2013; 72: 1488-1495
        • Chen Y.F.
        • Jobanputra P.
        • Barton P.
        • et al.
        A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
        Health Technol Assess. 2006; 10 (iii-iv, xi-xiii, 1-229)
        • Alonso-Ruiz A.
        • Pijoan J.I.
        • Ansuategui E.
        • Urkaregi A.
        • Calabozo M.
        • Quintana A.
        Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
        BMC Musculoskelet Disord. 2008; 9: 52
        • Bongartz T.
        • Warren F.C.
        • Mines D.
        • Matteson E.L.
        • Abrams K.R.
        • Sutton A.J.
        Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials.
        Ann Rheum Dis. 2009; 68: 1177-1183
        • Singh J.A.
        • Christensen R.
        • Wells G.A.
        • et al.
        A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
        CMAJ. 2009; 181: 787-796
        • Wiens A.
        • Correr C.J.
        • Pontarolo R.
        • Venson R.
        • Quinalha J.V.
        • Otuki M.F.
        A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis.
        Scand J Immunol. 2009; 70: 337-344
        • Wiens A.
        • Correr C.J.
        • Venson R.
        • Grochocki M.C.
        • Otuki M.F.
        • Pontarolo R.
        A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis.
        Clin Rheumatol. 2009; 28: 1365-1373
        • Singh J.A.
        • Noorbaloochi S.
        • Singh G.
        Golimumab for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2010; : CD008341
        • Wiens A.
        • Venson R.
        • Correr C.J.
        • Otuki M.F.
        • Pontarolo R.
        Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
        Pharmacotherapy. 2010; 30: 339-353
        • Askling J.
        • Fahrbach K.
        • Nordstrom B.
        • Ross S.
        • Schmid C.H.
        • Symmons D.
        Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
        Pharmacoepidemiol Drug Saf. 2011; 20: 119-130
        • Ruiz Garcia V.
        • Jobanputra P.
        • Burls A.
        • et al.
        Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
        Cochrane Database Syst Rev. 2011; : CD007649
        • Lethaby A.
        • Lopez-Olivo M.
        • Maxwell L.
        • Burls A.
        • Tugwell P.
        • Wells G.
        Etanercept for the treatment of rheumatoid arthritis.
        Cochrane Database Syst Rev. 2013; 5: CD004525
        • Dixon W.
        • Watson K.
        • Lunt M.
        • Hyrich K.
        • Silman A.
        • Symmons D.
        Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
        Arthritis Rheum. 2006; 54: 2368-2376
        • Wolfe F.
        • Caplan L.
        • Michaud K.
        Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy.
        Arthritis Rheum. 2006; 54: 628-634
        • Listing J.
        • Strangfeld A.
        • Kary S.
        • et al.
        Infections in patients with rheumatoid arthritis treated with biologic agents.
        Arthritis Rheum. 2005; 52: 3403-3412

      Appendix 2 Excluded References

        • Abe T.
        • Takeuchi T.
        • Miyasaka N.
        • et al.
        A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
        J Rheumatol. 2006; 33: 37-44
        • Abrahamyan L.
        • Beyene J.
        • Feng J.
        • et al.
        Response times follow lognormal or gamma distribution in arthritis patients.
        J Clin Epidemiol. 2010; 63: 1363-1369
        • Aletaha D.
        • Funovits J.
        • Breedveld F.C.
        • Sharp J.
        • Segurado O.
        • Smolen J.S.
        Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.
        Arthritis Rheum. 2009; : 1242-1249
        • Allaart C.F.
        • Breedveld F.C.
        • Dijkmans B.A.
        Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
        J Rheumatol Suppl. 2007; : 25-33
        • Allaart C.F.
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • Breedveld F.C.
        • Dijkmans B.A.
        Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
        Clin Exp Rheumatol. 2006; 24: S77-82
        • Anis A.
        • Zhang W.
        • Emery P.
        • et al.
        The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study.
        Rheumatology (Oxford). 2009; 48: 1283-1289
        • Antoni C.
        • Kalden J.R.
        Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
        Clin Exp Rheumatol. 1999; : S73-77
        • Antoni C.E.
        • Kavanaugh A.
        • Kirkham B.
        • et al.
        Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
        Arthritis Rheum. 2005; 52: 1227-1236
        • Baker J.F.
        • Baker D.G.
        • Toedter G.
        • Shults J.
        • Von Feldt J.M.
        • Leonard M.B.
        Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis.
        Clin Exp Rheumatol. 2012; 30: 658-664
        • Bankhurst A.D.
        Etanercept and methotrexate combination therapy.
        Clin Exp Rheumatol. 1999; 17: S69-72
        • Bathon J.M.
        • Fleischmann R.M.
        • Van der Heijde D.
        • et al.
        Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
        J Rheumatol. 2006; 33: 234-243
        • Baumgartner S.W.
        • Fleischmann R.M.
        • Moreland L.W.
        • Schiff M.H.
        • Markenson J.
        • Whitmore J.B.
        Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
        J Rheumatol. 2004; 31: 1532-1537
        • Bejarano V.
        • Conaghan P.G.
        • Quinn M.A.
        • Saleem B.
        • Emery P.
        Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.
        Rheumatology (Oxford). 2010; 49: 1971-1974
        • Bendtzen K.
        • Geborek P.
        • Svenson M.
        • Larsson L.
        • Kapetanovic M.C.
        • Saxne T.
        Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
        Arthritis Rheum. 2006; 54: 3782-3789
        • Benucci M.
        • Saviola G.
        • Baiardi P.
        • Manfredi M.
        • Sarzi-Puttini P.
        • Atzeni F.
        Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.
        Int J Immunopathol Pharmacol. 2011; 24: 269-274
        • Billiau A.D.
        • Loop M.
        • Le P.Q.
        • et al.
        Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
        Rheumatology (Oxford). 2010; : 1550-1558
        • Bliddal H.
        • Terslev L.
        • Qvistgaard E.
        • et al.
        A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
        Scand J Rheumatol. 2006; 35: 341-345
        • Blumenauer B.B.T.B.
        • Cranney A.
        • Burls A.
        • et al.
        Etanercept for the treatment of rheumatoid arthritis.
        Cochrane Database Syst Rev. 2003; (3)
        • Blumenauer B.B.T.B.
        • Judd M.
        • Wells George A.
        • et al.
        Inxfliximab for the treatment of rheumatoid arthritis.
        Cochrane Database Syst Rev. 2002; (3)
        • Boesen M.
        • Boesen L.
        • Jensen K.E.
        • et al.
        Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks.
        J Rheumatol. 2008; 35: 584-591
        • Breedveld F.C.
        • Emery P.
        • Keystone E.
        • et al.
        Infliximab in active early rheumatoid arthritis.
        Ann Rheum Dis. 2004; 63: 149-155
        • Breedveld F.C.
        • Han C.
        • Bala M.
        • et al.
        Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.
        Ann Rheum Dis. 2005; : 52-55
        • Brunner H.I.
        • Lovell D.J.
        • Finck B.K.
        • Giannini E.H.
        Preliminary definition of disease flare in juvenile rheumatoid arthritis.
        J Rheumatol. 2002; : 1058-1064
        • Capsoni F.
        • Sarzi-Puttini P.
        • Atzeni F.
        • et al.
        Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
        Arthritis Res Ther. 2005; 7: R250-255
        • Chang J.
        • Girgis L.
        Clinical use of anti-TNF-alpha biological agents–a guide for GPs.
        Aust Fam Physician. 2007; 36: 1035-1038
        • Chen D.Y.
        • Chou S.J.
        • Hsieh T.Y.
        • et al.
        Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
        J Formos Med Assoc. 2009; 108: 310-319
        • Chen H.A.
        • Lin K.C.
        • Chen C.H.
        • et al.
        The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2006; 65: 35-39
        • Choy E.H.
        • Hazleman B.
        • Smith M.
        • et al.
        Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
        Rheumatology (Oxford). 2002; 41: 1133-1137
        • Clark W.
        • Jobanputra P.
        • Barton P.
        • Burls A.
        The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
        Health Technol Assess. 2004; 8 (iii-iv, ix-x, 1-105)
        • Conaghan P.G.
        • Emery P.
        • Ostergaard M.
        • et al.
        Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
        Ann Rheum Dis. 2011; 70: 1968-1974
        • Criswell L.A.
        • Lum R.F.
        • Turner K.N.
        • et al.
        The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
        Arthritis Rheum. 2004; : 2750-2756
        • Cuomo G.
        • Molinaro G.
        • La Montagna G.
        • Migliaresi S.
        • Valentini G.
        [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
        Reumatismo. 2006; : 22-25
        • Curtis J.R.
        • Luijtens K.
        • Kavanaugh A.
        Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.
        Arthritis Care Res (Hoboken). 2012; 64: 658-667
        • Davis Jr., J.C.
        • Van Der Heijde D.
        • Braun J.
        • et al.
        Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
        Arthritis Rheum. 2003; 48: 3230-3236
        • De Filippis L.
        • Caliri A.
        • Anghelone S.
        • Scibilia G.
        • Lo Gullo R.
        • Bagnato G.
        Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
        Panminerva Med. 2006; 48: 129-135
        • De Stefano R.
        • Frati E.
        • Nargi F.
        • et al.
        Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
        Clin Rheumatol. 2010; 29: 517-524
        • de Vries-Bouwstra J.K.
        • Goekoop-Ruiterman Y.P.
        • Verpoort K.N.
        • et al.
        Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
        Arthritis Rheum. 2008; 58: 1293-1298
        • Delabaye I.
        • De Keyser F.
        74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.
        Arthritis Res Ther. 2010; 12: R121
        • den Broeder A.
        • van de Putte L.
        • Rau R.
        • et al.
        A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
        J Rheumatol. 2002; 29: 2288-2298
        • Dias E.M.
        • Lukas C.
        • Landewé R.
        • Fatenejad S.
        • van der Heijde D.
        Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis.
        Ann Rheum Dis. 2008; : 375-379
        • Durez P.
        • Malghem J.
        • Nzeusseu Toukap A.
        • et al.
        Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
        Arthritis Rheum. 2007; 56: 3919-3927
        • Durez P.
        • Nzeusseu Toukap A.
        • Lauwerys B.R.
        • et al.
        A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
        Ann Rheum Dis. 2004; 63: 1069-1074
        • Elliott M.J.
        • Maini R.N.
        • Feldmann M.
        • et al.
        Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
        Lancet. 1994; 344: 1105-1110
        • Emery P.
        • Fleischmann R.
        • van der Heijde D.
        • et al.
        The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
        Arthritis Rheum. 2011; 63: 1200-1210
        • Emery P.
        • Genovese M.C.
        • van Vollenhoven R.
        • Sharp J.T.
        • Patra K.
        • Sasso E.H.
        Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
        J Rheumatol. 2009; 36: 1429-1441
        • Emery P.
        • van der Heijde D.
        • Ostergaard M.
        • et al.
        Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2011; 70: 2126-2130
        • Englbrecht M.
        • Wang Y.
        • Ronneberger M.
        • et al.
        Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives.
        Arthritis Care Res (Hoboken). 2010; : 977-983
        • Engvall I.L.
        • Tengstrand B.
        • Brismar K.
        • Hafstrom I.
        Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.
        Arthritis Res Ther. 2010; 12: R197
        • Farahani P.
        • Levine M.
        • Goeree R.
        A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
        J Eval Clin Pract. 2006; : 463-470
        • Fasanmade A.A.
        • Adedokun O.J.
        • Ford J.
        • et al.
        Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
        Eur J Clin Pharmacol. 2009; 65: 1211-1228
        • Fernandez-Lopez C.
        • Blanco F.J.
        [ATTAIN study: efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-alpha].
        Reumatol Clin Suppl. 2006; : 34-43
        • Flint-Wagner H.G.
        • Lisse J.
        • Lohman T.G.
        • et al.
        Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.
        J Clin Rheumatol. 2009; 15: 165-171
        • Smolen J.S.
        • Han C.
        • van der Heijde D.M.
        • et al.
        Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
        Ann Rheum Dis. 2009; 68: 823-827
        • Furst D.E.
        • Gaylis N.
        • Bray V.
        • et al.
        Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
        Ann Rheum Dis. 2007; 66: 893-899
        • Garnero P.
        • Gineyts E.
        • Christgau S.
        • Finck B.
        • Delmas P.D.
        Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
        Arthritis Rheum. 2002; 46: 21-30
        • Genovese M.C.
        • Bathon J.M.
        • Fleischmann R.M.
        • et al.
        Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
        J Rheumatol. 2005; 32: 1232-1242
        • Genovese M.C.
        • Bathon J.M.
        • Martin R.W.
        • et al.
        Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
        Arthritis Rheum. 2002; 46: 1443-1450
        • Genovese M.C.
        • Becker J.C.
        • Schiff M.
        • et al.
        Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition.
        N Engl J Med. 2005; : 1114-1123
        • Genovese M.C.
        • Cohen S.
        • Moreland L.
        • et al.
        Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
        Arthritis Rheum. 2004; 50: 1412-1419
        • Genovese M.C.
        • Han C.
        • Keystone E.C.
        • et al.
        Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
        J Rheumatol. 2012; 39: 1185-1191
        • Gerlag D.M.
        • Hollis S.
        • Layton M.
        • et al.
        Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.
        Arthritis Rheum. 2010; : 3154-3160
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • Allaart C.F.
        • et al.
        Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
        Ann Rheum Dis. 2007; 66: 1227-1232
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • Allaart C.F.
        • et al.
        Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
        Ann Intern Med. 2007; : 406-415
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • Allaart C.F.
        • et al.
        Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
        Arthritis Rheum. 2005; 52: 3381-3390
        • Goldman J.A.
        • Xia H.A.
        • White B.
        • Paulus H.
        Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept.
        Ann Rheum Dis. 2006; 65: 1649-1652
        • Guler-Yuksel M.
        • Allaart C.F.
        • Watt I.
        • et al.
        Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
        Osteoarthritis Cartilage. 2010; 18: 1256-1262
        • Guler-Yuksel M.
        • Bijsterbosch J.
        • Goekoop-Ruiterman Y.P.
        • et al.
        Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
        Ann Rheum Dis. 2008; 67: 823-828
        • Guler-Yuksel M.
        • Klarenbeek N.B.
        • Goekoop-Ruiterman Y.P.
        • et al.
        Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
        Arthritis Res Ther. 2010; 12: R96
        • Han C.
        • Rahman M.U.
        • Doyle M.K.
        • et al.
        Association of anemia and physical disability among patients with rheumatoid arthritis.
        J Rheumatol. 2007; 34: 2177-2182
        • Han C.
        • Smolen J.
        • Kavanaugh A.
        • St Clair E.W.
        • Baker D.
        • Bala M.
        Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis.
        Arthritis Rheum. 2008; 59: 510-514
        • Hanauer S.B.
        • Feagan B.G.
        • Lichtenstein G.R.
        • et al.
        Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
        Lancet. 2002; : 1541-1549
        • Hasan U.
        Tumour necrosis factor inhibitors–what we need to know.
        N Z Med J. 2006; 119: U2336
        • Haugeberg G.
        • Conaghan P.G.
        • Quinn M.
        • Emery P.
        Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study.
        Ann Rheum Dis. 2009; 68: 1898-1901
        • Hoff M.
        • Kvien T.K.
        • Kalvesten J.
        • Elden A.
        • Haugeberg G.
        Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study.
        Ann Rheum Dis. 2009; 68: 1171-1176
        • Hoff M.
        • Kvien T.K.
        • Kalvesten J.
        • Elden A.
        • Kavanaugh A.
        • Haugeberg G.
        Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.
        BMC Musculoskelet Disord. 2011; 12: 54
        • Hsia E.C.
        • Cush J.J.
        • Matteson E.L.
        • et al.
        Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
        Arthritis Care Res (Hoboken). 2013; 65: 309-313
        • Hu C.
        • Xu Z.
        • Zhang Y.
        • Rahman M.U.
        • Davis H.M.
        • Zhou H.
        Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis.
        J Clin Pharmacol. 2011; 51: 639-648
        • Jamal S.
        • Patra K.
        • Keystone E.C.
        Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis.
        Clin Rheumatol. 2009; 28: 413-419
        • Jenks K.A.
        • Stamp L.K.
        • O'Donnell J.L.
        • Savage R.L.
        • Chapman P.T.
        Leflunomide-associated infections in rheumatoid arthritis.
        J Rheumatol. 2007; 34: 2201-2203
        • Johnsen A.K.
        • Schiff M.H.
        • Mease P.J.
        • et al.
        Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
        J Rheumatol. 2006; 33: 659-664
        • Joy M.S.
        • Gipson D.S.
        • Powell L.
        • et al.
        Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
        Am J Kidney Dis. 2010; 55: 50-60
        • Kaine J.L.
        • Kivitz A.J.
        • Birbara C.
        • Luo A.Y.
        Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
        J Rheumatol. 2007; 34: 272-279
        • Kameda H.
        • Ueki Y.
        • Saito K.
        • et al.
        Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
        Mod Rheumatol. 2010; 20: 531-538
        • Karaca-Mandic P.
        • Joyce G.F.
        • Goldman D.P.
        • Laouri M.
        Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
        Health Serv Res. 2010; 45: 1227-1250
        • Katchamart W.
        • Trudeau J.
        • Phumethum V.
        • Bombardier C.
        Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2010; : CD008495
        • Kavanaugh A.
        • Klareskog L.
        • van der Heijde D.
        • Li J.
        • Freundlich B.
        • Hooper M.
        Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.
        Ann Rheum Dis. 2008; 67: 1444-1447
        • Kavanaugh A.
        • Smolen J.S.
        • Emery P.
        • et al.
        Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
        Arthritis Rheum. 2009; 61: 1592-1600
        • Kavanaugh A.
        • St Clair E.W.
        • McCune W.J.
        • Braakman T.
        • Lipsky P.
        Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
        J Rheumatol. 2000; 27: 841-850
        • Kekow J.
        • Moots R.J.
        • Emery P.
        • et al.
        Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.
        Ann Rheum Dis. 2010; 69: 222-225
        • Keystone E.
        • Freundlich B.
        • Schiff M.
        • Li J.
        • Hooper M.
        Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
        J Rheumatol. 2009; 36: 522-531
        • Keystone E.
        • Genovese M.C.
        • Klareskog L.
        • et al.
        Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.
        Ann Rheum Dis. 2010; : 1129-1135
        • Keystone E.C.
        • Combe B.
        • Smolen J.
        • et al.
        Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
        Rheumatology (Oxford). 2012; 51: 1628-1638
        • Keystone E.C.
        • Curtis J.R.
        • Fleischmann R.M.
        • et al.
        Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
        J Rheumatol. 2011; 38: 990-996
        • Keystone E.C.
        • Haraoui B.
        • Bykerk V.P.
        Role of adalimumab in the treatment of early rheumatoid arthritis.
        Clin Exp Rheumatol. 2003; : S198-199
        • Keystone E.C.
        • Kavanaugh A.
        • Weinblatt M.E.
        • Patra K.
        • Pangan A.L.
        Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
        J Rheumatol. 2011; 38: 855-862
        • Keystone E.C.
        • Schiff M.H.
        • Kremer J.M.
        • et al.
        Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
        Arthritis Rheum. 2004; 50: 353-363
        • Kimel M.
        • Cifaldi M.
        • Chen N.
        • Revicki D.
        Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
        J Rheumatol. 2008; 35: 206-215
        • Kirwan John R.
        • Bijlsma Johannes W.J.
        • Boers M.
        • Shea B.
        Effects of glucocorticoids on radiological progression in rheumatoid arthritis.
        Cochrane Database Syst Rev. 2007; : CD006356
        • Klarenbeek N.B.
        • Guler-Yuksel M.
        • van der Heijde D.M.
        • et al.
        Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
        Ann Rheum Dis. 2010; 69: 2107-2113
        • Klarenbeek N.B.
        • Guler-Yuksel M.
        • van der Kooij S.M.
        • et al.
        The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
        Ann Rheum Dis. 2011; 70: 1039-1046
        • Klarenbeek N.B.
        • van der Kooij S.M.
        • Guler-Yuksel M.
        • et al.
        Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
        Ann Rheum Dis. 2011; 70: 315-319
        • Klarenbeek N.B.
        • van der Kooij S.M.
        • Huizinga T.J.
        • et al.
        Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.
        Ann Rheum Dis. 2010; : 1342-1345
        • Klareskog L.
        • Gaubitz M.
        • Rodriguez-Valverde V.
        • Malaise M.
        • Dougados M.
        • Wajdula J.
        A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs.
        Ann Rheum Dis. 2006; 65: 1578-1584
        • Kobelt G.
        • Lindgren P.
        • Singh A.
        • Klareskog L.
        Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
        Ann Rheum Dis. 2005; 64: 1174-1179
        • Kosinski M.
        • Kujawski S.C.
        • Martin R.
        • et al.
        Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
        Am J Manag Care. 2002; 8: 231-240
        • Kremer J.M.
        • Bloom B.J.
        • Breedveld F.C.
        • et al.
        The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
        Arthritis Rheum. 2009; 60: 1895-1905
        • Kremer J.M.
        • Weinblatt M.E.
        • Bankhurst A.D.
        • et al.
        Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
        Arthritis Rheum. 2003; 48: 1493-1499
        • Lahdenne P.
        • Vahasalo P.
        • Honkanen V.
        Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
        Ann Rheum Dis. 2003; : 245-247
        • Lan J.L.
        • Chou S.J.
        • Chen D.Y.
        • Chen Y.H.
        • Hsieh T.Y.
        • Young Jr., M.
        A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
        J Formos Med Assoc. 2004; 103: 618-623
        • Landewe R.
        • Van Der Heijde D.
        • Klareskog L.
        • Van Vollenhoven R.
        • Fatenejad S.
        Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
        Arthritis Rheum. 2006; : 3119-3125
        • Lee H.
        • Kimko H.C.
        • Rogge M.
        • Wang D.
        • Nestorov I.
        • Peck C.C.
        Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.
        Clin Pharmacol Ther. 2003; 73: 348-365
        • Lin Q.
        • Gu J.R.
        • Li T.W.
        • et al.
        Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis.
        Chin Med J (Engl). 2009; 122: 1784-1789
        • Lin Q.
        • Lin Z.
        • Gu J.
        • et al.
        Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment.
        Rheumatol Int. 2010; 30: 317-323
        • Lisbona M.P.
        • Maymo J.
        • Perich J.
        • Almirall M.
        • Carbonell J.
        Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept.
        Ann Rheum Dis. 2010; 69: 1117-1122
        • Lisbona M.P.
        • Maymo J.
        • Perich J.
        • Almirall M.
        • Perez-Garcia C.
        • Carbonell J.
        Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
        J Rheumatol. 2008; 35: 394-397
        • Lovell D.J.
        • Giannini E.H.
        • Reiff A.
        • et al.
        Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
        N Engl J Med. 2000; : 763-769
        • Lovell D.J.
        • Reiff A.
        • Ilowite N.T.
        • et al.
        Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
        Arthritis Rheum. 2008; : 1496-1504
        • Lovell D.J.
        • Ruperto N.
        • Goodman S.
        • et al.
        Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
        N Engl J Med. 2008; : 810-820
        • Lukas C.
        • van der Heijde D.
        • Fatenajad S.
        • Landewé R.
        Repair of erosions occurs almost exclusively in damaged joints without swelling.
        Ann Rheum Dis. 2010; : 851-855
        • Maksymowych W.P.
        • Mallon C.
        • Morrow S.
        • et al.
        Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index.
        Ann Rheum Dis. 2009; 68: 948-953
        • Maksymowych W.P.
        • Poole A.R.
        • Hiebert L.
        • et al.
        Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
        J Rheumatol. 2005; 32: 1911-1917
        • Maksymowych W.P.
        • Salonen D.
        • Inman R.D.
        • Rahman P.
        • Lambert R.G.
        Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.
        J Rheumatol. 2010; 37: 1728-1734
        • Marcora S.M.
        • Chester K.R.
        • Mittal G.
        • Lemmey A.B.
        • Maddison P.J.
        Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.
        Am J Clin Nutr. 2006; 84: 1463-1472
        • Mariette X.
        • Ravaud P.
        • Steinfeld S.
        • et al.
        Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS).
        Arthritis Rheum. 2004; 50: 1270-1276
        • Masiero S.
        • Boniolo A.
        • Wassermann L.
        • Machiedo H.
        • Volante D.
        • Punzi L.
        Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial.
        Clin Rheumatol. 2007; 26: 2043-2050
        • Mathias S.D.
        • Colwell H.H.
        • Miller D.P.
        • Moreland L.W.
        • Buatti M.
        • Wanke L.
        Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.
        Clin Ther. 2000; 22: 128-139
        • Maxwell L.
        • Singh Jasvinder A.
        Abatacept for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2009; : CD007277
        • Mease P.J.
        Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
        Skin Therapy Lett. 2003; : 1-4
        • Mease P.J.
        • Goffe B.S.
        • Metz J.
        • VanderStoep A.
        • Finck B.
        • Burge D.J.
        Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
        Lancet. 2000; 356: 385-390
        • Mease P.J.
        • Hobbs K.
        • Chalmers A.
        • et al.
        Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
        Ann Rheum Dis. 2009; 68: 1247-1254
        • Merkel P.A.
        • Lo G.H.
        • Holbrook J.T.
        • et al.
        Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.
        Ann Intern Med. 2005; 142: 620-626
        • Mertens M.
        • Singh Jasvinder A.
        Anakinra for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2009; : CD005121
        • Moreland L.W.
        • Bucy R.P.
        • Weinblatt M.E.
        • Mohler K.M.
        • Spencer-Green G.T.
        • Chatham W.W.
        Immune function in patients with rheumatoid arthritis treated with etanercept.
        Clin Immunol. 2002; 103: 13-21
        • Moreland L.W.
        • Genovese M.C.
        • Sato R.
        • Singh A.
        Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis.
        Arthritis Rheum. 2006; 55: 287-293
        • Moreland L.W.
        • Weinblatt M.E.
        • Keystone E.C.
        • et al.
        Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
        J Rheumatol. 2006; 33: 854-861
        • Navarro-Sarabia F.
        • Ariza-Ariza R.
        • Hernandez-Cruz B.
        • Villanueva I.
        Adalimumab for treating rheumatoid arthritis.
        Cochrane Database Syst Rev. 2005; : CD005113
        • Nestorov I.
        • Zitnik R.
        • DeVries T.
        • Nakanishi A.M.
        • Wang A.
        • Banfield C.
        Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
        Br J Clin Pharmacol. 2006; 62: 435-445
        • Osiri M.
        • Shea B.
        • Welch V.
        • et al.
        Leflunomide for the treatment of rheumatoid arthritis.
        Cochrane Database Syst Rev. 2002;
        • Ostergaard M.
        • Emery P.
        • Conaghan P.G.
        • et al.
        Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
        Arthritis Rheum. 2011; 63: 3712-3722
        • Pavelka K.
        • Jarosova K.
        • Suchy D.
        • et al.
        Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
        Ann Rheum Dis. 2009; 68: 1285-1289
        • Perera L.C.
        • Tymms K.E.
        • Wilson B.J.
        • et al.
        Etanercept in severe active rheumatoid arthritis: first Australian experience.
        Intern Med J. 2006; 36: 625-631
        • Perkins D.J.
        • St Clair E.W.
        • Misukonis M.A.
        • Weinberg J.B.
        Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2).
        Arthritis Rheum. 1998; 41: 2205-2210
        • Peters M.J.
        • Watt P.
        • Cherry L.
        • et al.
        Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies.
        Ann Rheum Dis. 2010; 69: 1687-1690
        • Pincus T.
        • Amara I.
        • Segurado O.G.
        • Bergman M.
        • Koch G.G.
        Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials.
        J Rheumatol. 2008; : 201-205
        • Quinn M.A.
        • Conaghan P.G.
        • O'Connor P.J.
        • et al.
        Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
        Arthritis Rheum. 2005; 52: 27-35
        • Rahman M.U.
        • Strusberg I.
        • Geusens P.
        • et al.
        Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2007; 66: 1233-1238
        • Rau R.
        • Simianer S.
        • van Riel P.L.
        • et al.
        Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
        Scand J Rheumatol. 2004; : 145-153
        • Ruiz Garcia V.
        • Jobanputra P.
        • Burls A.
        • et al.
        Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
        Cochrane Database Syst Rev. 2011; : CD007649
        • Ruperto N.
        • Lovell D.J.
        • Cuttica R.
        • et al.
        A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
        Arthritis Rheum. 2007; : 3096-3106
        • Ruperto N.
        • Lovell D.J.
        • Cuttica R.
        • et al.
        Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
        Ann Rheum Dis. 2010; : 718-722
        • Saleem B.
        • Mackie S.
        • Quinn M.
        • et al.
        Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?.
        Ann Rheum Dis. 2008; 67: 1178-1180
        • Sandborn W.J.
        • Hanauer S.B.
        • Katz S.
        • et al.
        Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
        Gastroenterology. 2001; 121: 1088-1094
        • Sankar V.
        • Brennan M.T.
        • Kok M.R.
        • et al.
        Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
        Arthritis Rheum. 2004; 50: 2240-2245
        • Sany J.
        • Kaiser M.J.
        • Jorgensen C.
        • Trape G.
        Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis.
        Ann Rheum Dis. 2005; 64: 1647-1649
        • Scheinberg M.
        • Guedes-Barbosa L.S.
        • Mangueira C.
        • et al.
        Yellow fever revaccination during infliximab therapy.
        Arthritis Care Res (Hoboken). 2010; 62: 896-898
        • Schneeweiss S.
        • Setoguchi S.
        • Weinblatt M.E.
        • et al.
        Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
        Arthritis Rheum. 2007; 56: 1754-1764
        • Schoels M.
        • Aletaha D.
        • Funovits J.
        • Kavanaugh A.
        • Baker D.
        • Smolen J.S.
        Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
        Ann Rheum Dis. 2010; 69: 1441-1447
        • Sennels H.
        • Sorensen S.
        • Ostergaard M.
        • et al.
        Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate.
        Scand J Rheumatol. 2008; 37: 241-247
        • Singh Jasvinder A.
        • Beg S.
        • Lopez-Olivo Maria A.
        Tocilizumab for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2010; : CD008331
        • Singh J.A.
        • Christensen R.
        • Wells George A.
        • et al.
        Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
        Cochrane Database Syst Rev. 2009; : CD007848
        • Singh J.A.
        • Noorbaloochi S.
        • Singh G.
        Golimumab for rheumatoid arthritis.
        Cochrane Database Syst Rev. 2010; : CD008341
        • Smeets T.J.
        • Kraan M.C.
        • van Loon M.E.
        • Tak P.P.
        Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.
        Arthritis Rheum. 2003; 48: 2155-2162
        • Smith J.A.
        • Thompson D.J.
        • Whitcup S.M.
        • et al.
        A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
        Arthritis Rheum. 2005; : 18-23
        • Smolen J.S.
        • Aletaha D.
        Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
        Arthritis Rheum. 2011; 63: 43-52
        • Smolen J.S.
        • Han C.
        • Bala M.
        • et al.
        Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
        Arthritis Rheum. 2005; 52: 1020-1030
        • Smolen J.S.
        • Han C.
        • van der Heijde D.
        • et al.
        Infliximab treatment maintains employability in patients with early rheumatoid arthritis.
        Arthritis Rheum. 2006; 54: 716-722
        • Smolen J.S.
        • Kay J.
        • Landewe R.B.
        • et al.
        Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
        Ann Rheum Dis. 2012; 71: 1671-1679
      1. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. Jul 18 2009;374(9685):210-221.

        • Smolen J.S.
        • van der Heijde D.M.
        • Aletaha D.
        • et al.
        Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
        Ann Rheum Dis. 2009; 68: 1535-1540
        • Smolen J.S.
        • Van Der Heijde D.M.
        • St Clair E.W.
        • et al.
        Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
        Arthritis Rheum. 2006; 54: 702-710
        • Solomon D.H.
        The comparative safety and effectiveness of TNF-alpha antagonists [corrected].
        J Manag Care Pharm. 2007; 13: S7-18
        • Soubrier M.
        • Lukas C.
        • Sibilia J.
        • et al.
        Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort.
        Ann Rheum Dis. 2011; 70: 611-615
        • Soubrier M.
        • Puechal X.
        • Sibilia J.
        • et al.
        Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
        Rheumatology (Oxford). 2009; 48: 1429-1434
        • Souto-Carneiro M.M.
        • Mahadevan V.
        • Takada K.
        • et al.
        Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.
        Arthritis Res Ther. 2009; 11: R84
        • St Clair E.W.
        • Wagner C.L.
        • Fasanmade A.A.
        • et al.
        The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
        Arthritis Rheum. 2002; : 1451-1459
        • Strand V.
        • Mease P.
        • Burmester G.R.
        • et al.
        Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
        Arthritis Res Ther. 2009; 11: R170
        • Strand V.
        • Smolen J.S.
        • van Vollenhoven R.F.
        • et al.
        Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
        Ann Rheum Dis. 2011; 70: 996-1002
        • Takahashi H.
        • Shigehara K.
        • Yamamoto M.
        • et al.
        Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration.
        Rheumatol Int. 2007; 27: 1143-1148
        • Takeuchi T.
        • Miyasaka N.
        • Inoue K.
        • Abe T.
        • Koike T.
        Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study.
        Mod Rheumatol. 2009; 19: 478-487
        • Takeuchi T.
        • Miyasaka N.
        • Tatsuki Y.
        • et al.
        Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2011; 70: 1208-1215
        • Taylor P.C.
        • Ritchlin C.
        • Mendelsohn A.
        • et al.
        Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
        J Rheumatol. 2011; 38: 2572-2580
        • Taylor P.C.
        • Steuer A.
        • Gruber J.
        • et al.
        Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.
        Arthritis Rheum. 2004; : 1107-1116
        • Taylor P.C.
        • Steuer A.
        • Gruber J.
        • et al.
        Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
        Arthritis Rheum. 2006; : 47-53
        • van den Hout W.B.
        • Goekoop-Ruiterman Y.P.
        • Allaart C.F.
        • et al.
        Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
        Arthritis Rheum. 2009; 61: 291-299
        • van der Bijl A.E.
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • et al.
        Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.
        Arthritis Rheum. 2007; 56: 2129-2134
        • van der Heijde D.
        • Breedveld F.C.
        • Kavanaugh A.
        • et al.
        Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
        J Rheumatol. 2010; 37: 2237-2246
        • van der Heijde D.
        • Burmester G.
        • Melo-Gomes J.
        • et al.
        Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
        Ann Rheum Dis. 2009; : 1113-1118
        • van der Heijde D.
        • Burmester G.
        • Melo-Gomes J.
        • et al.
        The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
        Ann Rheum Dis. 2008; 67: 182-188
        • van der Heijde D.
        • Keystone E.C.
        • Curtis J.R.
        • et al.
        Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
        J Rheumatol. 2012; 39: 1326-1333
        • van der Heijde D.
        • Klareskog L.
        • Boers M.
        • et al.
        Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.
        Ann Rheum Dis. 2005; 64: 1582-1587
        • van der Heijde D.
        • Klareskog L.
        • Singh A.
        • et al.
        Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
        Ann Rheum Dis. 2006; 65: 328-334
        • van der Heijde D.
        • Landewe R.
        • Einstein S.
        • et al.
        Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
        Arthritis Rheum. 2008; 58: 1324-1331
        • van der Heijde D.
        • Landewe R.
        • Klareskog L.
        • et al.
        Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.
        Arthritis Rheum. 2005; 52: 49-60
        • van der Heijde D.
        • Landewé R.
        • van Vollenhoven R.
        • Fatenejad S.
        • Klareskog L.
        Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
        Ann Rheum Dis. 2008; : 1267-1270
        • van der Kooij S.M.
        • de Vries-Bouwstra J.K.
        • Goekoop-Ruiterman Y.P.
        • et al.
        Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
        Arthritis Rheum. 2009; 61: 4-12
        • van der Kooij S.M.
        • de Vries-Bouwstra J.K.
        • Goekoop-Ruiterman Y.P.
        • et al.
        Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
        Ann Rheum Dis. 2007; 66: 1356-1362
        • van der Kooij S.M.
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • et al.
        Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
        Ann Rheum Dis. 2009; 68: 914-921
        • van der Kooij S.M.
        • le Cessie S.
        • Goekoop-Ruiterman Y.P.
        • et al.
        Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
        Ann Rheum Dis. 2009; 68: 1153-1158
        • van Riel P.L.
        • Freundlich B.
        • MacPeek D.
        • et al.
        Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
        Ann Rheum Dis. 2008; : 1104-1110
        • van Riel P.L.
        • Taggart A.J.
        • Sany J.
        • et al.
        Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
        Ann Rheum Dis. 2006; 65: 1478-1483
        • van Vollenhoven R.F.
        • Cifaldi M.A.
        • Ray S.
        • Chen N.
        • Weisman M.H.
        Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
        Arthritis Care Res (Hoboken). 2010; 62: 226-234
        • van Vollenhoven R.F.
        • Felson D.
        • Strand V.
        • Weinblatt M.E.
        • Luijtens K.
        • Keystone E.C.
        American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
        Arthritis Care Res (Hoboken). 2011; 63: 128-134
        • van Vollenhoven R.F.
        • Kinnman N.
        • Vincent E.
        • Wax S.
        • Bathon J.
        Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
        Arthritis Rheum. 2011; 63: 1782-1792
        • Vastesaeger N.
        • Xu S.
        • Aletaha D.
        • St Clair E.W.
        • Smolen J.S.
        A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
        Rheumatology (Oxford). 2009; 48: 1114-1121
        • Vgontzas A.N.
        • Zoumakis E.
        • Lin H.M.
        • Bixler E.O.
        • Trakada G.
        • Chrousos G.P.
        Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist.
        J Clin Endocrinol Metab. 2004; : 4409-4413
        • Visser K.
        • Goekoop-Ruiterman Y.P.
        • de Vries-Bouwstra J.K.
        • et al.
        A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
        Ann Rheum Dis. 2010; 69: 1333-1337
        • Visvanathan S.
        • Keenan G.F.
        • Baker D.G.
        • Levinson A.I.
        • Wagner C.L.
        Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.
        J Rheumatol. 2007; 34: 952-957
        • Visvanathan S.
        • Marini J.C.
        • Smolen J.S.
        • et al.
        Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
        J Rheumatol. 2007; 34: 1465-1474
        • Visvanathan S.
        • Wagner C.
        • Rojas J.
        • et al.
        E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
        J Rheumatol. 2009; 36: 1371-1379
        • Visvanathan S.
        • Wagner C.
        • Smolen J.
        • et al.
        IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
        Arthritis Rheum. 2006; : 2840-2844
        • Wang S.Y.
        • Liu Y.Y.
        • Ye H.
        • et al.
        Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis.
        J Rheumatol. 2011; 38: 821-827
        • Weinblatt M.
        • Schiff M.
        • Goldman A.
        • et al.
        Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
        Ann Rheum Dis. 2007; 66: 228-234
        • Weinblatt M.E.
        • Keystone E.C.
        • Furst D.E.
        • Kavanaugh A.F.
        • Chartash E.K.
        • Segurado O.G.
        Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
        Ann Rheum Dis. 2006; 65: 753-759
        • Weinblatt M.E.
        • Kremer J.M.
        • Bankhurst A.D.
        • et al.
        A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
        N Engl J Med. 1999; 340: 253-259
        • Weinblatt M.E.
        • Schiff M.H.
        • Ruderman E.M.
        • et al.
        Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
        Arthritis Rheum. 2008; 58: 1921-1930
        • Weisman M.H.
        • Moreland L.W.
        • Furst D.E.
        • et al.
        Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
        Clin Ther. 2003; 25: 1700-1721
        • Westhovens R.
        • Houssiau F.
        • Joly J.
        • et al.
        A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
        J Rheumatol. 2006; 33: 847-853
        • Wolfe F.
        • Michaud K.
        Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
        Arthritis Rheum. 2004; 50: 1740-1751
        • Wolfe F.
        • Michaud K.
        The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
        Arthritis Rheum. 2007; 56: 1433-1439
        • Wong M.
        • Oakley S.P.
        • Young L.
        • et al.
        Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2009; 68: 1277-1284
        • Wood K.L.
        • Hage C.A.
        • Knox K.S.
        • et al.
        Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.
        Am J Respir Crit Care Med. 2003; 167: 1279-1282
        • Yount S.
        • Sorensen M.V.
        • Cella D.
        • Sengupta N.
        • Grober J.
        • Chartash E.K.
        Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.
        Clin Exp Rheumatol. 2007; 25: 838-846
        • Zhou H.
        • Buckwalter M.
        • Boni J.
        • et al.
        Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.
        Int J Clin Pharmacol Ther. 2004; 42: 267-276
        • Zhou H.
        • Jang H.
        • Fleischmann R.M.
        • et al.
        Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
        J Clin Pharmacol. 2007; 47: 383-396
        • Zhou H.
        • Mayer P.R.
        • Wajdula J.
        • Fatenejad S.
        Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
        J Clin Pharmacol. 2004; 44: 1235-1243
        • Zhuang Y.
        • Xu Z.
        • Frederick B.
        • et al.
        Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
        Clin Ther. 2012; 34: 77-90